Advanced Science, EarlyView.HmmyCAFs may form a triple immunosuppressive niche: possibly secrete ECM (POSTN, etc.) as physical barriers to block CD8⁺ T cells, induce CD8⁺ T exhaustion via those molecules, and use HIF‐1α‐driven metabolism to create acidic, nutrient‐poor microenvironments that suppress T cells.
Yingxue Li +12 more
wiley +1 more source
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]
, 2018 In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A. +4 more
core +1 more source
Mechanism of Lenvatinib Resistance via Exosomal miRNA‐132/Nrf2 Axis in Hepatocellular Carcinoma
Annals of Gastroenterological Surgery, EarlyView.Exosomal miRNA‐132 from LVT‐res HCC cells activated Nrf2 expression through the PTEN/GSK3β pathway in recipient cells. This cascade could induce drug resistance in non‐resistant HCC cells in the TME. ABSTRACT Introduction Lenvatinib is a multiple receptor tyrosine kinase inhibitor and a first‐line targeted therapy for hepatocellular carcinoma (HCC ...
Chie Takasu +7 more
wiley +1 more source
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. [PDF]
, 2008 The clinical success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles. It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of ...
Aizenstein, Brian +9 more
core
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]
, 2017 Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W +11 more
core +1 more source
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials
American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.ABSTRACT RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular‐derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
Sara Gil‐Bernabé +5 more
wiley +1 more source
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]
, 2018 Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V. +3 more
core +1 more source
Approaches to Enhance Photodynamic Therapy of Lung Cancer: Potential Application of Nanoparticles
Advanced NanoBiomed Research, EarlyView.Bioactive ligand‐targeted nanocarriers can accommodate functionalization with numerous targeting ligands for effective delivery of photosensitizers (PSs) within targeted photodynamic therapy. Various targeting moieties including peptides, antibodies, carbohydrates, aptamers, proteins, and PS anticancer molecules can be attached to nanomaterials.
Nokuphila Winifred Nompumelelo Simelane +1 more
wiley +1 more source
Emerging role of the pentose phosphate pathway in hepatocellular carcinoma [PDF]
, 2017 In recent years, there has been a revival of interest in metabolic changes of cancer cells as it has been noticed that malignant transformation and metabolic reprogramming are closely intertwined.
Columbano, Amedeo +2 more
core +2 more sources
Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia
British Journal of Clinical Pharmacology, EarlyView.Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is a therapeutic option in these cases.
Paul Dalmas +7 more
wiley +1 more source